Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CARM 
Carisma Therapeutics Inc. (CARM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/30/2025: CARM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $1
1 Year Target Price $1
| 1 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -2.62% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 2.44M USD | Price to earnings Ratio - | 1Y Target Price 1 |
Price to earnings Ratio - | 1Y Target Price 1 | ||
Volume (30-day avg) 2 | Beta 3.81 | 52 Weeks Range 0.03 - 1.27 | Updated Date 10/31/2025 |
52 Weeks Range 0.03 - 1.27 | Updated Date 10/31/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.19 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -409.69% |
Management Effectiveness
Return on Assets (TTM) -85.68% | Return on Equity (TTM) -362.79% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 10983785 | Price to Sales(TTM) 0.23 |
Enterprise Value 10983785 | Price to Sales(TTM) 0.23 | ||
Enterprise Value to Revenue 1.02 | Enterprise Value to EBITDA -0.06 | Shares Outstanding 41788096 | Shares Floating 30079072 |
Shares Outstanding 41788096 | Shares Floating 30079072 | ||
Percent Insiders 26.6 | Percent Institutions 19.8 |
Upturn AI SWOT
Carisma Therapeutics Inc.
Company Overview
History and Background
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies. Founded to pioneer the development of macrophage-based therapeutics. Significant milestones include advancements in CAR-Macrophage technology and clinical trial initiations.
Core Business Areas
- CAR-Macrophage Immunotherapy: Focuses on developing chimeric antigen receptor (CAR)-engineered macrophages to treat solid tumors. Their main approach involves modifying macrophages to target and destroy cancer cells.
Leadership and Structure
The leadership team consists of experienced professionals in the biotechnology and pharmaceutical industries. Organizational structure involves research and development, clinical operations, and corporate management teams.
Top Products and Market Share
Key Offerings
- CT-0508 (CAR-Macrophage Therapy): An autologous CAR-macrophage therapy targeting HER2-positive solid tumors. Currently in Phase 1 clinical trials. Competitors include companies developing CAR-T cell therapies and other immunotherapy approaches for solid tumors, such as Allogene Therapeutics (ALLO) and Fate Therapeutics (FATE).
Market Dynamics
Industry Overview
The immunotherapy market is rapidly growing, driven by advancements in cancer treatment. Solid tumors represent a significant unmet need.
Positioning
Carisma Therapeutics is positioned as a pioneer in CAR-macrophage technology, offering a potentially novel approach to treat solid tumors. Competitive advantages include the unique mechanism of action of macrophages compared to CAR-T cells.
Total Addressable Market (TAM)
The TAM for solid tumor immunotherapies is estimated to be in the tens of billions of dollars. Carisma is positioned to capture a portion of this market with its innovative CAR-macrophage approach.
Upturn SWOT Analysis
Strengths
- Pioneering CAR-Macrophage Technology
- Novel Approach for Solid Tumors
- Strong Scientific Team
Weaknesses
- Early Stage Clinical Development
- Limited Clinical Data
- High R&D Costs
Opportunities
- Partnerships with Larger Pharmaceutical Companies
- Expansion into New Cancer Indications
- Positive Clinical Trial Results
Threats
- Competition from Established Immunotherapy Companies
- Clinical Trial Failures
- Regulatory Hurdles
Competitors and Market Share
Key Competitors
- Allogene Therapeutics (ALLO)
- Fate Therapeutics (FATE)
- Bristol Myers Squibb (BMY)
- Johnson & Johnson (JNJ)
Competitive Landscape
Carisma's advantages include its novel CAR-macrophage platform. Disadvantages include being an early-stage company competing with larger, established players.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by advancing its CAR-macrophage technology and initiating clinical trials.
Future Projections: Future growth depends on the success of its clinical programs and potential partnerships.
Recent Initiatives: Recent initiatives include progressing its CAR-macrophage therapy for HER2-positive solid tumors into later-stage clinical trials.
Summary
Carisma Therapeutics is an early-stage biopharmaceutical company pioneering CAR-macrophage therapy, which is a novel approach in the immunotherapy field. Its strength lies in its unique technology; however, it faces risks due to early clinical stages and strong competition. Successful clinical trial results and strategic partnerships are critical for future growth. The company is still developing and may be a risky investment opportunity for investors.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Press Releases
Disclaimers:
This analysis is based on publicly available information and represents an opinion, not financial advice. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Carisma Therapeutics Inc.
Exchange NASDAQ | Headquaters Philadelphia, PA, United States | ||
IPO Launch date 2014-02-06 | President, CEO & Director Mr. Steven Kelly | ||
Sector Healthcare | Industry Biotechnology | Full time employees 46 | Website https://www.carismatx.com |
Full time employees 46 | Website https://www.carismatx.com | ||
Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidate includes CT-2401, which is in preclinical trail for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others. In addition, it develops in vivo CAR-M cell therapy to treat solid tumors, including hepatocellular carcinoma. Carisma Therapeutics, Inc. has collaboration and license agreement with ModernaTX, Inc. to address oncology gene therapies. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. Carisma Therapeutics, Inc. was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.